Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 16/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 3/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL278808 | 0.91 | KRAS (0.45) | KRASITGB3ITGAVITGB5CACNA1B | |
| SCHEMBL278805 | 0.89 | ITGB3 (0.46) | KRASITGB3ITGAVITGB5CACNA1B | |
| SCHEMBL278801 | 0.84 | CACNA1B (0.51) | KRASITGB3ITGAVITGB5CACNA1B | |
| SCHEMBL278647 | 0.80 | CACNA1B (0.46) | KRASITGB3ITGAVITGB5CACNA1B | |
| SCHEMBL9448586 | 0.80 | TPSAB1 (0.46) | ITGB3ITGAVITGB5 | |
| SCHEMBL9448577 | 0.80 | TPSAB1 (0.46) | ITGB3ITGAVITGB5 | |
| SCHEMBL14885799 | 0.80 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL13107808 | 0.80 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL12808284 | 0.80 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 | |
| SCHEMBL21475019 | 0.80 | ITGB3 (0.55) | ITGB3ITGAVITGB5ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133472-B2 | Cyclopeptides containing RGD mimetics as imaging markers for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133472-B2 | Cyclopeptides containing RGD mimetics as imaging markers for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009134382-A2 | CYCLOPEPTIDES CONTAINING RGD MIMETICS AS IMAGING MARKERS FOR INTEGRINS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074844-A1 | Cyclopeptides Containing RGD Mimetics As Imaging Markers For Integrins | ITGB3, ITGAV, ITGB1 | KRAS 3545/4885ITGB3 1/4885ITGAV 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.